comprehensive -WSS

comprehensive

author：explore 2025-09-27 15:59:01 - browse：243

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Prime Medicine, Myeloid Therapeutics clash over genome

hotspot

WSS

Study finds new variant for Parkinson’s in African populations

AstraZeneca bets AAV gene therapy will still deliver the goods

David Ricks of Eli Lilly: best biopharma CEO of 2023

Drinking less cuts risk of oral cavity, esophageal cancer: Report

FDA panel gives mixed vote on blood pressure devices

AstraZeneca bets AAV gene therapy will still deliver the goods

leisure time

comprehensive

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

Hospitals owned by private equity see complications spike 25%

Drug repurposing or repositioning? The language matters

FDA panel gives mixed vote on blood pressure devices

DIEP, the 'gold standard' of breast reconstruction, is under threat

CDC advisory panel says seniors 'may' get RSV vaccine

Medical records are filled with copy

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

After affirmative action ruling, medical educators look to 'holistic review'

Prime Medicine, Myeloid Therapeutics clash over genome

explore

How Long Island became the ‘eugenics capital of the world’

SNAP should offer more nutrition education

AstraZeneca challenges Medicare drug negotiation program

SEC charges former device maker CEO with $41 million fraud

Medicare explains how it will choose drugs for negotiation

AstraZeneca bets AAV gene therapy will still deliver the goods

hotspot

hotspot

hotspot

hotspot